Synapse - Clinical outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg type treated in the rituximab era: Long-term follow-up of a single-center experience

Clinical outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg type treated in the rituximab era: Long-term follow-up of a single-center experience Meeting Abstract

Authors:	Falchi, L.; Qiu, A.; Ewalt, M. D.; Batlevi, C. L.; Caron, P. C.; Hamlin, P. A.; Hamilton, A.; Horwitz, S. M.; Joffe, E.; Khan, N.; Kumar, A.; Moskowitz, A. J.; Noy, A.; Owens, C.; Palomba, M. L.; Straus, D. J.; von Keudell, G.; Zelenetz, A. D.; Dogan, A.; Busam, K.; Myskowski, P.; Yahalom, J.; Salles, G.; Matasar, M. J.
Abstract Title:	Clinical outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg type treated in the rituximab era: Long-term follow-up of a single-center experience
Meeting Title:	63nd Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	138
Issue:	Suppl. 1
Meeting Dates:	2021 Dec 11-14
Meeting Location:	Atlanta, GA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2021-11-23
Language:	English
ACCESSION:	WOS:000736413902030
DOI:	10.1182/blood-2021-151994
PROVIDER:	wos
Notes:	Meeting Abstract: 2513 -- Hybrid meeting, also took place online -- Source: Wos